Építés alatt – nem éles oldal

Ugrás a tartalomra

Frontlight Research

Vizsgálati helyszín

Tom Baker Cancer Centre

Calgary, Alberta T2N 4N2, KanadaMég nincs intézményhez kötve

23futó vizsgálat
33lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 56 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Prosztatarák8 vizsgálat
Akut mieloid leukémia (AML)5 vizsgálat
Mielóma multiplex5 vizsgálat
Petefészekrák5 vizsgálat
Áttétes emlőrák4 vizsgálat
Fej-nyaki daganatok3 vizsgálat
Méhtestrák3 vizsgálat
Melanóma3 vizsgálat
Mielodiszplasztikus szindróma (MDS)3 vizsgálat
Mieloproliferatív neopláziák3 vizsgálat
Tripla negatív emlőrák3 vizsgálat
Tüdőrák3 vizsgálat
és még 17
Fázis: 3. fázis25 vizsgálat
2. fázis13 vizsgálat
1. fázis4 vizsgálat
1/2. fázis4 vizsgálat
2/3. fázis2 vizsgálat
Állapot: Lezárult29 vizsgálat
Fut, nem toboroz20 vizsgálat
Leállították4 vizsgálat
Toboroz2 vizsgálat
Még nem toboroz1 vizsgálat
Fő szponzor: Canadian Cancer Trials Group9 vizsgálat
Pfizer4 vizsgálat
Radiation Therapy Oncology Group4 vizsgálat
University Health Network, Toronto3 vizsgálat
Amgen2 vizsgálat
és még 31

Futó vizsgálatok

Fut, nem toboroz
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
NCT05481151· 3. fázis· PharmaEssentia· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
NCT04663997· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
NCT03938987· 1/2. fázis· University of Alberta· Forrás
Contact: Dr. Peter Duggan, MD
Fut, nem toboroz
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
NCT04217356· University Health Network, Toronto· Forrás
Fut, nem toboroz
Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer
NCT04197141· 2. fázis· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Forrás
Fut, nem toboroz
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
NCT04150887· 1. fázis· OncoVerity, Inc.· Forrás
Toboroz
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883· Melanoma and Skin Cancer Trials Limited· Forrás
Contact: Melanoma and Skin Cancer Trials Coordinator
Toboroz
Chemoradiotherapy for Advanced Esophageal Cancer
NCT02297217· 2. fázis· AHS Cancer Control Alberta· Forrás
Contact: Marc Kerba, MD
Fut, nem toboroz
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
NCT03480776· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Multiple Myeloma Molecular Monitoring Study
NCT03421132· Horizon Health Network· Forrás
Fut, nem toboroz
Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer
NCT03210103· London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's· Forrás
Fut, nem toboroz
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
NCT03016338· 2. fázis· University Health Network, Toronto· Forrás
Fut, nem toboroz
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030· 1/2. fázis· Celgene· Forrás
Fut, nem toboroz
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT02489006· 2. fázis· University Health Network, Toronto· Forrás
Fut, nem toboroz
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT02598661· 2/3. fázis· Geron Corporation· Forrás
Fut, nem toboroz
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423· 1/2. fázis· Taiho Oncology, Inc.· Forrás
Fut, nem toboroz
Economic Analysis of Alliance A041202 CLL Study
NCT02414022· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
NCT01396408· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT01368588· 3. fázis· Radiation Therapy Oncology Group· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Leállították
Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy
NCT05137899· 2. fázis· Ontario Clinical Oncology Group (OCOG)· Forrás
Leállították
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
NCT05275439· 1. fázis· Shattuck Labs, Inc.· Forrás
Lezárult
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203· 3. fázis· AVEO Pharmaceuticals, Inc.· Forrás
Lezárult
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
NCT04266795· 2. fázis· Takeda· Forrás
Lezárult
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
NCT04224272· 2. fázis· Jazz Pharmaceuticals· Forrás
Lezárult
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
NCT04303780· 3. fázis· Amgen· Forrás
Lezárult
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855· 3. fázis· AbbVie· Forrás
Lezárult
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT03529110· 3. fázis· Daiichi Sankyo· Forrás
Leállították
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
NCT03031821· 3. fázis· Canadian Urologic Oncology Group· Forrás
Lezárult
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
NCT03517449· 3. fázis· Eisai Inc.· Forrás
Lezárult
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
NCT03260894· 3. fázis· Incyte Corporation· Forrás
Lezárult
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
NCT03269136· 1. fázis· Pfizer· Forrás
Lezárult
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
NCT03268954· 3. fázis· Takeda· Forrás
Lezárult
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03277105· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
NCT03112174· 3. fázis· Pharmacyclics LLC.· Forrás
Lezárult
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02975934· 3. fázis· pharmaand GmbH· Forrás
Lezárult
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
NCT02784171· 2/3. fázis· Canadian Cancer Trials Group· Forrás
Toboroz
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
NCT02869802· British Columbia Cancer Agency· Forrás
Contact: Daniel J Renouf, MD
Leállították
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT02675452· 1. fázis· Amgen· Forrás
Lezárult
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT02632448· 1/2. fázis· Esperas Pharma Inc.· Forrás
Lezárult
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
NCT02576431· 2. fázis· Bayer· Forrás
Lezárult
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
NCT02273375· 3. fázis· Canadian Cancer Trials Group· Forrás
Lezárult
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NCT02254278· 2. fázis· NRG Oncology· Forrás
Lezárult
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
NCT02003924· 3. fázis· Pfizer· Forrás
Lezárult
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
NCT01909453· 3. fázis· Pfizer· Forrás
Lezárult
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
NCT01730937· 3. fázis· Radiation Therapy Oncology Group· Forrás
Lezárult
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
NCT01740427· 3. fázis· Pfizer· Forrás
Lezárult
Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
NCT01658930· Canadian Cancer Trials Group· Forrás
Lezárult
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
NCT01546987· 3. fázis· Radiation Therapy Oncology Group· Forrás
Lezárult
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
NCT01650701· 3. fázis· The Lymphoma Academic Research Organisation· Forrás
Lezárult
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
NCT00936390· 3. fázis· Radiation Therapy Oncology Group· Forrás
Lezárult
Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
NCT00819208· Canadian Cancer Trials Group· Forrás
Lezárult
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
NCT00066690· 3. fázis· ETOP IBCSG Partners Foundation· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 13.